<DOC>
	<DOCNO>NCT00244621</DOCNO>
	<brief_summary>This dose range study candesartan cilexetil hypertensive pediatric subject age 1 less 6 year age . It employ double blind , randomize , dose range design intend conduct multicenter trial . There 3 study 'periods ' : 1-week placebo run-in , 4-week double blind treatment , 52-week open-label , long-term treatment period . Subjects undergo screen evaluation , 1-week single-blind , placebo run-in , eligible subject allocate receive 1 3 dose level candesartan cilexetil ( 0.05 mg/kg , 0.20 mg /kg 0.40 mg /kg ) , liquid formulation , 1:1:1 ratio 4-weeks . At end randomize dose allocation ( Day 28 ) , blood pressure assessment perform subject may begin 52-week , open-label treatment period study .</brief_summary>
	<brief_title>Atacand Dose Ranging Hypertensive Pediatric Subjects 1 Year Less Than 6 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Signed informed consent parent legal guardian . Weight &gt; 10 kg &lt; 40 kg . SiSBP and/or SiDBP &gt; 95th percentile &lt; 20 mm Hg ( systolic ) and/or 10 mm Hg ( diastolic ) 95th percentile screen randomization base heightadjusted chart age gender . Any situation , clinical condition laboratory abnormality , opinion investigator sponsor , may interfere subject 's participation study would pose significant risk subject interfere assessment safety efficacy endpoint . Weight &lt; 10 kg &gt; 40 kg . Less 80 % compliance study medication singleblind placebo screen assessed residual medication volume . Hypertension secondary pheochromocytoma , hyperthyroidism , Cushing 's Syndrome . Uncorrected coarctation aorta , bilateral renal artery renal artery stenosis single kidney . Estimated glomerular filtration rate ( GFR ) &lt; 50 mL/min/1.73m 2 base Schwartz Formula ( Schwartz et al , 1987 ) . Renal transplant &lt; 6 month prior study entry . Subjects receive renal transplant &gt; 6 month prior study entry may participate study : 1 ) renal function stable , 2 ) estimate GFR &gt; 50 mL/min/1.73m 2 , 3 ) stable dos immunosuppressive medication anticipate throughout 4week , doubleblind period study , 4 ) episode acute allograft rejection occur within 30 day study entry , 5 ) renal allograft document renal artery stenosis . Nephrotic syndrome remission . Unstable insulin dependent diabetes mellitus . Known bleeding , coagulation , platelet disorder could interfere blood sampling . Clinically significant valvular heart disease . Clinical diagnosis heart failure . Clinically significant arrhythmia ( eg , arrhythmia require medical therapy cause symptom ) . Second third degree AV block . Impaired liver function define either acute liver disease chronic liver disease persistent liver enzyme value great 1Â½ time upper limit reference range aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) . Known hypersensitivity ARBs . Currently receive angiotensin receptor blocker angiotensin convert enzyme inhibitor investigator 's judgment safely withdrawn study . Subjects receive angiotensin receptor blocker angiotensin convert enzyme inhibitor may eligible undergo withdrawal antihypertensive medication 2week washout period subsequently meet BP inclusion/exclusion criterion . Subjects currently receive class antihypertensive medication ( eg , diuretic , calcium channel blocker betablockers ) whose BP value meet inclusion/exclusion criterion may participate study continue current antihypertensive medication regimen . Up 2 concomitant antihypertensive medication permit . Doses dose regimen concomitant antihypertensive medication must remain unchanged 4week doubleblind period study . Currently use , use within 14 day prior receive doubleblind medication , concomitant medication opinion investigator could negatively affect subject . Unable unwilling comply study requirement include blood sample swallow study drug suspension .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Pediatric hypertension</keyword>
</DOC>